(Fig. 1) The trials enrolled patients with early AD, meaning the clinical stage of MCI due to AD or mild AD dementia according to NIA-AA diagnostic criteria as determined by positive Aβ and tau biomarkers in cerebrospinal fluid (CSF) or positron emission tomography (PET). The gene discussed is MAPT; the disease is Alzheimer disease.